"Illumina sharply increased its spending on lobbying over the past two years as it tried to build support against antitrust regulators in the US and Europe that have attempted to block its $8bn acquisition of cancer testing company Grail."

https://www.ft.com/content/5298eddf-8ddb-49e5-ad20-df5c2021a053